
The Silent Threat of Heart Failure with Preserved Ejection Fraction
Heart Failure with Preserved Ejection Fraction (HFpEF) is a complex and challenging condition to manage. Early identification and appropriate treatment are crucial for improving patient outcomes. However, traditional methods of assessing HFpEF often lack precision and timeliness, hindering effective patient care.

The Devastating Impact of Heart Failure with Preserved Ejection Fraction
HFpEF significantly impacts patients’ quality of life, leading to reduced independence, increased healthcare utilization, and higher mortality rates. Early detection and intervention are essential for preventing hospitalizations and improving patient outcomes.

Kribado: Your Partner in Heart Failure Management
Revolutionize Heart Failure Care with Instant Risk Assessment
Kribado is an innovative patient screening solution designed to accurately and efficiently assess the risk of HFpEF. By leveraging the HLSS and advanced algorithms, Kribado empowers healthcare providers to optimize treatment plans and improve patient outcomes.
How Kribado Works
- Rapid HFpEF Risk Assessment: Quickly assess patient heart failure with preserved ejection fraction risk.
- Data-Driven Insights: Gain valuable information to tailor treatment plans.
- Improved Patient Outcomes: Enhance patient well-being and overall heart health.
- Efficient Workflow Integration: Seamlessly integrate HFpEF risk assessments into clinical practice.

Indigital Technologies – Trusted by Pharmaceutical Leaders
Indigital Technologies LLP is a proven leader in pharmaceutical business growth. With a strong track record of delivering innovative solutions, we are committed to improving patient care and driving industry progress.